Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be ...

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

Moderna's RSV vaccine earned approval last May, but sales haven't gotten off the ground yet. The biotech company expects to lose money again in 2025, but operating expenses are declining.

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

U.S. equities rose at midday on optimism the new tariffs threatened by President Trump won't be as severe as initially believed.